<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002092'>Pulmonary hypertension</z:hpo> is a common but underdiagnosed complication of <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo>, which can be associated with significant morbidity and early mortality </plain></SENT>
<SENT sid="1" pm="."><plain>Although often associated with anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> antibodies, the etiology remains poorly understood </plain></SENT>
<SENT sid="2" pm="."><plain>In case reports and small open trials, the anti-CD20, B-cell targeted therapeutic antibody, rituximab, has been reported to provide benefits for <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> patients with <z:hpo ids='HP_0000099'>glomerulonephritis</z:hpo>, anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> antibody syndrome, <z:hpo ids='HP_0002633'>vasculitis</z:hpo>, <z:hpo ids='HP_0001369'>arthritis</z:hpo>, and refractory <z:e sem="disease" ids="C0037274" disease_type="Disease or Syndrome" abbrv="">skin disease</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>However, the outcome of rituximab treatment of pulmonary arterial <z:hpo ids='HP_0000822'>hypertension</z:hpo> associated with <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> has not been described </plain></SENT>
<SENT sid="4" pm="."><plain>We, therefore, present a case of a young <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> patient with early <z:hpo ids='HP_0003674'>onset</z:hpo> of pulmonary arterial <z:hpo ids='HP_0000822'>hypertension</z:hpo> during the disease course, refractory to multiple treatment modalities, who had significant improvement with rituximab therapy </plain></SENT>
</text></document>